KYNB
Kyntra Bio, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$8.55
+0.71%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.6M | 6.4M | 29.6M | 46.8M | 140.7M |
| Cost of Revenue | 3.8M | 556.0K | 15.6M | 4.0M | 20.3M |
| Gross Profit | 838.0K | 5.9M | 14.1M | 42.8M | 120.5M |
| Operating Expenses | |||||
| R&D Expense | 22.9M | 23.5M | 95.7M | 266.5M | 296.8M |
| SG&A Expense | 28.2M | 27.7M | 49.3M | 86.5M | 124.7M |
| General & Admin Expense | 9.3M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 586.0K | 553.0K | 19.5M | 12.6M | — |
| Total Operating Expenses | 51.7M | 51.8M | 164.5M | 365.6M | 421.5M |
| Cost and Expenses | 55.5M | 52.3M | 180.0M | 369.5M | 441.8M |
| Operating Income (EBIT) | (50.8M) | (45.9M) | (150.4M) | (322.7M) | (301.0M) |
| Non-Operating | |||||
| Interest Income | 5.0M | 2.9M | 5.3M | 7.6M | 7.6M |
| Interest Expense | 9.3M | 8.8M | 8.2M | 8.1M | 1.4M |
| Net Interest Income | (4.3M) | (5.8M) | (3.0M) | (501.0K) | 6.2M |
| Other Non-Op Income/Expense | 19.9M | (12.4M) | (3.0M) | (501.0K) | 7.7M |
| Non-Operating Income (excl Interest) | 43.4M | 12.4M | (5.3M) | (7.6M) | (7.6M) |
| EBT (Pre-Tax Income) | (30.9M) | (58.3M) | (153.4M) | (323.2M) | (293.3M) |
| Income Tax Expense | (1.0K) | (90.0K) | (269.0K) | (252.0K) | 358.0K |
| Bottom Line | |||||
| Net Income | 183.2M | 183.5M | (47.6M) | (284.2M) | (293.7M) |
| Earnings from Cont. Ops | (30.9M) | (58.2M) | (153.1M) | (323.0M) | (293.7M) |
| Earnings from Discont. Ops | 214.2M | 241.7M | 105.5M | 38.7M | — |
| Bottom Line Net Income | 183.2M | 183.5M | (47.6M) | (284.2M) | (293.7M) |
| Per Share | |||||
| Basic EPS | $58.19 | $45.37 | ($0.48) | ($2.92) | ($3.15) |
| Diluted EPS | $58.19 | $45.37 | ($0.48) | ($2.92) | ($3.15) |
| Revenue Per Share | $1.14 | $1.59 | $7.40 | $12.03 | $37.60 |
| Shares | |||||
| Basic Shares Outstanding | 4.0M | 4.0M | 4.0M | 3.9M | 3.7M |
| Diluted Shares Outstanding | 4.0M | 4.0M | 4.0M | 3.9M | 3.7M |
| Profitability Metrics | |||||
| EBITDA | (94.0M) | (57.5M) | (142.4M) | (305.2M) | (282.8M) |
| D&A | 207.0K | 748.0K | 2.7M | 9.9M | 10.6M |
| EBIT | (94.2M) | (58.3M) | (145.1M) | (315.1M) | (293.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026